China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Investor Update - February 14, 2020 Category: Pharmaceuticals Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Media News - February 14, 2020 Category: Pharmaceuticals Source Type: news

Absent p53, oral cancers recruit and reprogram nerves to fuel tumor growth
(University of Texas M. D. Anderson Cancer Center) Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function and recruiting them to the tumor, where they fuel growth and cancer progress. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 12, 2020 Category: Cancer & Oncology Source Type: news

TAT 2020 Honorary Award: A recognition in cancer drug development to Lillian Siu
(European Society for Medical Oncology) The European Society for Medical Oncology is pleased to announce that Lillian L. Siu, Professor at the University of Toronto and Medical Oncologist at the Princess Margaret Cancer Centre, Toronto, will receive the TAT 2020 Honorary Award in recognition of her pivotal contributions in the development of new anticancer drugs, particularly with respect to phase I trials in head and neck malignancies. The award will be presented during the ESMO Targeted Anticancer Therapies Congress, to be held in Paris, France, March 2-4. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 11, 2020 Category: International Medicine & Public Health Source Type: news

Roche to present new data on Tecentriq in combination with Avastin that shows improvement in overall survival for Chinese patients with the most common form of liver cancer
Basel, 7 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that additional data will be presented from a cohort of Chinese patients in the Phase III IMbrave150 study that evaluated Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Data from 194 Chinese patients who took part in the IMbrave150 study were consistent with the global results, that showed a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free...
Source: Roche Investor Update - February 7, 2020 Category: Pharmaceuticals Source Type: news

Botanical drug is shown to help patients with head and neck cancers
In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are located in the head and the neck. APG-157 is made up of multiple compounds produced by plants, including curcumin. UCLA Jonsson Comprehensive Cancer Center researchers found that treatment with this botanical drug resulted in (Source: World Pharma News)
Source: World Pharma News - February 6, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Gaps in cure rate appear linked to race and insurance status for common HPV-related cancer
(National Comprehensive Cancer Network) Largest population-based analysis to date on outcomes for HPV-positive oropharyngeal squamous cell carcinoma of the head and neck (SCCHN) finds significant racial and socioeconomic disparities, according to new research in JNCCN-Journal of the National Comprehensive Cancer Network. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 6, 2020 Category: Cancer & Oncology Source Type: news

Botanical drug is shown to help patients with head and neck cancers
(University of California - Los Angeles Health Sciences) In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are located in the head and the neck. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 6, 2020 Category: International Medicine & Public Health Source Type: news

Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer
In this study, locally advanced head and neck cancer patients undergoing definitive chemoradiation were randomly allocated to weekly cisplatin - radiation {CRT arm} or nimotuzumab -weekly cisplatin -radiation {NCRT arm}. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 6, 2020 Category: Cancer & Oncology Source Type: news

Botanical drug is shown to help patients with head and neck cancers
In this study, UCLA researchers found that when APG-157 is taken through oral mucosal absorption, patients have high levels of curcumin circulating in their blood and absorbed by cancer tissues.METHODUCLA researchers conducted the study of APG-157 comparing 12 people who had oral and oropharyngeal cancer with a control group of 13 people who did not have cancer. The reason both the people with cancer and without cancer were part of the study was to show that the drug was not toxic to either people with cancer or those without cancer.The medication was given each hour for three hours and was delivered as a lozenge that slow...
Source: UCLA Newsroom: Health Sciences - February 6, 2020 Category: Universities & Medical Training Source Type: news

Varying Overall Survival Indicated Depending on Institution for Patients with HNC
Patients with head and neck cancer saw better overall survival when treated at academic comprehensive cancer programs and integrated network cancer programs, compared to comprehensive community cancer programs and community cancer programs. (Source: CancerNetwork)
Source: CancerNetwork - January 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Omitting Level 2b in Selective Neck Dissection May Improve Shoulder Function Among Patients
Treating head and neck cancer with selective neck dissection showed an improvement in shoulder function when level 2b neck dissection was omitted in treatment, according to a recent study. (Source: CancerNetwork)
Source: CancerNetwork - January 30, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
      ·Application is being reviewed under FDA ’s Real-Time Oncology Review pilot programmeBasel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectab le hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, wh...
Source: Roche Investor Update - January 27, 2020 Category: Pharmaceuticals Source Type: news

Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer
Basel, 24 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasiv e urothelial cancer (MIUC). Safety for Tecentriq appeared consistent with the known safety profile of the medicine, and no new safety signals were identified.“Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we w...
Source: Roche Media News - January 24, 2020 Category: Pharmaceuticals Source Type: news

Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer
            Basel, 24 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasiv e urothelial cancer (MIUC). Safety for Tecentriq appeared consistent with the known safety profile of the medicine, and no new safety signals were identified.“Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is ve...
Source: Roche Investor Update - January 24, 2020 Category: Pharmaceuticals Source Type: news

Head/neck cancer diagnosis, time to treatment after ACA Medicaid expansions
(JAMA Network) Researchers for this observational study examined the association between the expansion of Medicaid coverage in some states after the Patient Protection and Affordable Care Act (ACA) was passed and the diagnosis and treatment of patients with head and neck squamous cell carcinoma (HNSCC). The analysis included nearly 91,000 adults with newly diagnosed HNSCC who were identified from the National Cancer Database. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 16, 2020 Category: Cancer & Oncology Source Type: news

Mortality Risk in Oropharynx Cancer Varies Based on HPV Status
Patients with OPC with HPV - negative tumors have increased risk for head and neck cancer mortality (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 13, 2020 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Infections, Internal Medicine, Oncology, ENT, Pathology, Journal, Source Type: news

Mortality Risk in Oropharynx Cancer Varies Based on HPV Status
MONDAY, Jan. 13, 2020 -- For patients with oropharynx cancer, the rates of head and neck cancer (HNC) mortality and competing mortality vary depending on human papillomavirus (HPV) status, with increased risks for HNC mortality and competing... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 13, 2020 Category: Pharmaceuticals Source Type: news

Medtech in a Minute: A Huge Merger Flop, a TAVR Breakthrough, and More
Illumina-PacBio Merger Axed Illumina and PacBio called off a $1.2 billion merger after FTC ran interference, saying the pairing could create a monopoly in the next-generation sequencing market. Illumina will now pay PacBio a termination fee of $98 million.   Breakthrough Device Designation Signals a Promising Year for TAVR FDA granted JenaValve a breakthrough device designation for pericardial transcatheter aortic valve replacement (TAVR) system, signaling another promising year for the space. The designation is for severe aortic regurgitation (AR) and AR-dominant mixed aorti...
Source: MDDI - January 10, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Zap Surgical Raises $81M for RadioSurgical Robot
Zap Surgical’s latest move shows investors continue to rally around the surgical robotics market. The San Carlos, CA-based company has raised $81 million equity financing round and has developed Zap-X, an FDA-cleared radiosurgical robot for the treatment of cancer and other brain disorders. The financing round was led by Primavera Capital Group, with participation from GT Healthcare Capital Partners, Chow Tai Fook Enterprises, ShangBay Capital, and Hogy Medical, who joined existing investors Foxconn Technology Group and Varian Medical Systems. Funds from the financing round will be used to accelerate the ...
Source: MDDI - January 10, 2020 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Nanobiotix plans head and neck cancer treatment trial
Nanotech radiation therapy technology developer Nanobiotix said it will launch...Read more on AuntMinnie.com (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 8, 2020 Category: Radiology Source Type: news

Uppaluri Awarded $4.3M Cancer Moonshot Grant from NCI/NIDCR
Ravindra Uppaluri, MD, PhD, chief of the Division of Otolaryngology in the Department of Surgery and chief of Head and Neck Surgical Oncology at Dana-Farber and Brigham and Women ’s Cancer Center, received a $4.3 million U01 Cancer Moonshot grant from (Source: BWH News)
Source: BWH News - January 2, 2020 Category: Hospital Management Source Type: news

Acupuncture May Ease a Common Side Effect of Cancer Treatment, Dry Mouth
FRIDAY, Dec. 27, 2019 -- Dry mouth can be a troubling side effect of radiation therapy, but acupuncture may ease its symptoms, a new study suggests. Of 339 patients getting radiation for head and neck cancer in the United States and China, those... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 27, 2019 Category: General Medicine Source Type: news

Head and neck cancer symptoms: One symptom of the deadly disease you should never ignore
HEAD and neck cancers affect the mouth, nose and throat and is a deadly disease that is becoming more and more prevalent. There is an easily missed sign of the condition that one should look out for. What is it? (Source: Daily Express - Health)
Source: Daily Express - Health - December 20, 2019 Category: Consumer Health News Source Type: news

Possible strategy for cancer treatment found in nuclear transport proteins
(Kanazawa University) The nuclear import of proteins befalls through nuclear pore complexes (NPCs) and normally requires specific transport proteins. A type of a nuclear transport protein plays a key role in the proliferation and resistance to treatment of head and neck squamous carcinoma cells, report researchers at Kanazawa University. The results suggest that targeting specific nuclear transport systems may lead to possible therapeutic strategies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2019 Category: Cancer & Oncology Source Type: news

FDA Grants Fast Track Designation to Tipifarnib for the Treatment of Patients with HNSCC
The drug candidate tipifarnib (Zarnestra) is being clinically studied for the treatment of patients with  HRAS-mutant head and neck squamous cell carcinoma after progression on platinum therapy.  (Source: CancerNetwork)
Source: CancerNetwork - December 16, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma
             Basel, 13 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS). The study showed adding Tecentriq ® (atezolizumab) to Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) helped to reduce the risk of disease worsening or death, compared to placebo plus Cotellic and Zelboraf. A significant and clinically meaningful improvement in PFS was demonstrated in the study. The safety ...
Source: Roche Investor Update - December 13, 2019 Category: Pharmaceuticals Source Type: news

True Acupuncture Shows Promise for Patients with Head and Neck Cancer
True acupuncture resulted in fewer and less severe radiation-induced xerostomia symptoms in this phase III study. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

2012 to 2014 Saw 41,185 U.S. Patients With Skin Malignancy
MONDAY, Dec. 9, 2019 -- From 2012 to 2014, 41,185 patients with a diagnosis of skin malignancy of the head and neck region were identified, mostly with a diagnosis of nonmelanoma skin cancer (NMSC), according to a study recently published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 9, 2019 Category: Pharmaceuticals Source Type: news

Acupuncture reduces radiation-induced dry mouth for cancer patients
(University of Texas M. D. Anderson Cancer Center) After receiving acupuncture treatment three days a week during the course of radiation treatment, head and neck cancer patients experienced less dry mouth, according to study results from researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2019 Category: Cancer & Oncology Source Type: news

RSNA: Brachytherapy Treats Skin Cancer in Elderly Patients
THURSDAY, Dec. 5, 2019 -- Excellent local control and cosmetic outcomes are observed in elderly patients receiving high dose-rate brachytherapy (HDRBT) for early-stage nonmelanoma skin cancer of the head and neck region, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2019 Category: Pharmaceuticals Source Type: news

Program to address opioid prescribing for lung, head and neck cancer patients
(University of Illinois at Chicago) The University of Illinois at Chicago has received a grant from the Coleman Foundation to develop a screening process for prescribing opioids and managing opioid use disorders in cancer patients who receive care at UI Health, UIC's clinical health enterprise. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2019 Category: Cancer & Oncology Source Type: news

Late Stage Head and Neck Cancer in the U.S. Sees Increasing Incidence
Researchers found that there is an increasing incidence of late stage head and neck cancer in the U.S., highlighting the need for continuous public health efforts toward early detection. (Source: CancerNetwork)
Source: CancerNetwork - November 25, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Cancer immunotherapy drug 'less toxic and prolongs life'
Pembrolizumab held advanced head and neck cancers in a group of patients at bay for around two years. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 23, 2019 Category: Consumer Health News Source Type: news

Less Frequent Surveillance Scan Policies Effective for Patients with Head and Neck Cancer
A new possible surveillance model suggests scanning patients with head and neck cancer treated with radiotherapy less frequently could be more cost-effective and time-effective. (Source: CancerNetwork)
Source: CancerNetwork - November 22, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

New Cochrane Review assesses different HPV vaccines and vaccine schedules in adolescent girls and boys
New evidence published in the Cochrane Library today provides further information on the benefits and harms of different human papillomavirus (HPV) vaccines and vaccine schedules in young women and men.HPV is the most common viral infection of the reproductive tract in both women and men globally (WHO 2017). Most people who have sexual contact will be exposed to HPV at some point in their life. In most people, their own immune system will clear the HPV infection.HPV infection can sometimes persist if the immune system does not clear the virus. Persistent infection with some ‘high-risk’ strains of HPV can lead t...
Source: Cochrane News and Events - November 20, 2019 Category: Information Technology Authors: Katie Abbotts Source Type: news

First Cancer Patient Treated with Varian ProBeam Compact Proton Therapy System at Treatment ...
PALO ALTO, Calif., Nov. 18, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced the South Florida Proton Therapy Institute (SFPTI), a Proton International facility, on the campus of Delray Medical Center, has treated its first patient utilizing the Varian ProBeam® Compact single-room proton therapy system. Proton therapy can be used to treat many types of tumors including in the brain, head and neck, central nervous system and lung, and more precisely targets cancer cells...This story is related to the following:Radiotherapy Systems (Source: Industrial Newsroom - Health, Medical and Dental Supplies)
Source: Industrial Newsroom - Health, Medical and Dental Supplies - November 19, 2019 Category: Medical Devices Source Type: news

Pembrolizumab: New Standard of Care in Head and Neck Cancer Pembrolizumab: New Standard of Care in Head and Neck Cancer
Use of pembrolizumab alone and in combination with chemotherapy has led to significantly improved overall survival in patients with metastatic or recurrent head and neck cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 15, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Pembrolizumab Prolongs Survival in Advanced Head, Neck Cancer
THURSDAY, Nov. 14, 2019 -- The checkpoint inhibitor pembrolizumab prolongs survival in patients with certain head and neck cancers, according to a phase 3 study published online Oct. 31 in The Lancet. Barbara Burtness, M.D., from the Yale University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 15, 2019 Category: Pharmaceuticals Source Type: news

HPV-Linked Head and Neck Cancer on the Rise
Title: HPV-Linked Head and Neck Cancer on the RiseCategory: Health NewsCreated: 11/5/2019 12:00:00 AMLast Editorial Review: 11/6/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 6, 2019 Category: Cancer & Oncology Source Type: news

Head and neck cancer patients benefited from Affordable Care Act
(Saint Louis University) The rate of uninsured patients with head and neck cancers was 'significantly reduced' following the implementation of the federal Patient Protection and Affordable Care Act (ACA). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 6, 2019 Category: Cancer & Oncology Source Type: news

Yale Cancer Center study shows checkpoint inhibitor prolongs survival in pa
Compared to the standard therapy, survival was significantly improved for participants with previously untreated recurrent or metastatic head and neck cancers. (Source: Yale Science and Health News)
Source: Yale Science and Health News - November 1, 2019 Category: Universities & Medical Training Source Type: news

Checkpoint inhibitor prolongs survival with certain head and neck cancers
Compared to the standard therapy, survival was significantly improved for participants with previously untreated recurrent or metastatic head and neck cancers. (Source: Yale Science and Health News)
Source: Yale Science and Health News - November 1, 2019 Category: Universities & Medical Training Source Type: news

Study shows Affordable Care Act benefited adults with head, neck cancers
Levels of uninsured people with head and neck cancer declined by 3 percent following implementation of Affordable Care Act. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 31, 2019 Category: Consumer Health News Source Type: news

Tipifarnib Shows Responses in HRAS-Mutant Head and Neck Cancers
A new inhibitor may help patients with a certain subset of head and neck squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - October 30, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

Medical News Today: New blood test detects brain tumors with 87% accuracy
Researchers have recently published 'the first demonstration' that a promising blood test for detecting brain cancer works in the clinic. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 11, 2019 Category: Consumer Health News Tags: Head and Neck Cancer Source Type: news

Grail Stays at Forefront of Liquid Biopsy Conversation with New Results
Newly-released data is putting Grail back in the forefront of the liquid biopsy conversation. The Menlo Park, CA-based company announced data validating the performance of its investigational multi-cancer early detection blood test for the first time in an independent cohort of participants. The validation data is coming from both the Circulating Cell-Free Genome Atlas (CCGA) study. Data show Grail’s liquid biopsy test was shown to detect more than 20 cancer types across all stages with a single, very low false-positive rate. Grail will present the results at an American Society of Clinical Oncology Break...
Source: MDDI - October 11, 2019 Category: Medical Devices Authors: Omar Ford Tags: IVD Source Type: news

Medical News Today: Thyroid cancer: New test could reduce unnecessary diagnostic surgeries
A new test that looks for a chemical fingerprint of thyroid cancer in fine needle aspiration samples may improve the accuracy of preoperative diagnosis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 10, 2019 Category: Consumer Health News Tags: Head and Neck Cancer Source Type: news

Aethlon Takes Big Steps in Oncology with New IDE
Aethlon Medical is making traction in the move to extend the Hemopurifier’s reach in the oncology market. On Monday, FDA granted the San Diego-based company’s Hemopurifier an IDE to initiate an early feasibility study of the Hemopurifier in patients with head and neck cancer in combination with standard of care pembrolizumab (KeyTruda). Aethlon’s early feasibility study will enroll 10 to 12 patients at a single center. The primary endpoint for the study will be safety, with secondary endpoints including measures of exosome clearance and characterization, as well as resp...
Source: MDDI - October 8, 2019 Category: Medical Devices Authors: Omar Ford Tags: Regulatory and Compliance Source Type: news

Incidence of HPV-Positive Head and Neck Cancer Up in the U.S.
TUESDAY, Oct. 1, 2019 -- The rate of head and neck cancers has risen since the 1970s, and most are linked to human papillomavirus (HPV), according to a study recently published in Cancer Epidemiology, Biomarkers& Prevention. Brandon A. Mahal,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 1, 2019 Category: Pharmaceuticals Source Type: news